Urol. praxi, 2015; 16(5): 210-212
A brief on overview of current therapeutic possibilities of the bone disease in prostate cancer
- Onkologická klinika, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice v Olomouci
Bone disease represents a serious medical problem in most patiens with advanced prostate cancer. There exists not only systemic therapy
targeting the tumour but also therapy aiming mainly the bone affected by prostate cancer cells. The article summarizes briefly treatment
modalities affecting the bone disease in prostate cancer patiens and its current role in prostate cancer therapy.
Keywords: advanced prostate cancer, bone disease, BMA, radionuclides
Published: December 1, 2015 Show citation
References
- Miller DC, Hafez KS, Stewart A, et al. Prostate carcinoma presentation, diagnosis, and staging: an update from the National Cancer Data Base. Cancer 2003; 98: 1169-1178.
Go to original source... 
Go to PubMed... - Snedecor SJ, Carter JA, Kaura S, et al. Denosumab versus zolendronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. J Med Econ 2013; 16: 19-29. Go to original source... Go to PubMed...
- Fizazi K, Massard C, Smith M, et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol. 2015 Jul; 68(1): 42-50. Go to original source... Go to PubMed...
- Rajpar S, Massard C, Laplanche A, et al. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Ann Oncol. 2010 Sep; 21(9): 1864-1869. Go to original source... Go to PubMed...
- Cook RJ, Coleman R, Brown J,et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2006 Jun 1; 12(11 Pt 1): 3361-3367. Go to original source... Go to PubMed...
- Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zolendronic acid for the prevention of skeletal complications in patiens with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882. Go to original source... Go to PubMed...
- Gartrell BA, Coleman R, Efstathiou E, et al. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. Eur Urol. 2015 Jul 4. Go to original source... Go to PubMed...
- Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zolendronic acid for preventiv of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48: 3082-3092. Go to original source... Go to PubMed...
- Smith MR, Saad F, Coleman R, et al.Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46. Go to original source... Go to PubMed...
- Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013; 31: 3800-3806. Go to original source... Go to PubMed...
- Nilsson S, Franzen L, Oarker C, et al. Bone-targeted radium-223 in symptomatic,hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 587-594. Go to original source... Go to PubMed...
- Parker CC, Pascoe S, Chodacki A, et al. A randomized,double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patiens with bone metastases and castration-resistant prostate cancer. Eur Urol 2013; 63: 189-197. Go to original source... Go to PubMed...
- Parker C, Nilsson S, Heinrich D, et al. ALSYMPCA Investigators Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223. Go to original source... Go to PubMed...
- Hoskin P, Sartor O, O'Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014 Nov; 15(12): 1397-1406. Go to original source... Go to PubMed...
- Fitzpatrick JM, Bellmunt J, Fizazi K, et al. Optimal management of metastatic castration-resistant prostate cancer. Highlights from a European Expert Consensus Panel. Eur J Cancer 2014; 50: 1617-1627. Go to original source... Go to PubMed...